JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

7.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.41

Max

7.66

Põhinäitajad
By Trading Economics
Sissetulek	3M 12M
Müük	21M 76M
P/E Sektori keskmine	12.312 67.147
Kasumimarginaal	15.633
Töötajad	179
EBITDA	13M 27M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-33.69% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	24M 382M
Eelmine avamishind	7.49
Eelmine sulgemishind	7.49

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 23:08 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 23:07 UTC

Tulu

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:20 UTC

Tulu

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. apr 2026, 23:22 UTC

Tulu

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. apr 2026, 22:52 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:33 UTC

Tulu

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. apr 2026, 22:05 UTC

Tulu

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 21:57 UTC

Tulu

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. apr 2026, 21:55 UTC

Tulu

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. apr 2026, 21:53 UTC

Tulu

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-33.69% langus

12 kuu keskmine prognoos

Keskmine 5 USD -33.69%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.